Status:
COMPLETED
Specified Drug Use-results Survey of Betanis Tablets
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Overactive Bladder
Eligibility:
All Genders
Brief Summary
To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- diagnosed as OAB and treated with mirabegron
- diagnosed as glaucoma (including normal tension glaucoma)
- having intraocular pressure measurement conducted more than twice within six months before the start of the mirabegron treatment
Exclusion
Key Trial Info
Start Date :
December 4 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01898624
Start Date
December 4 2012
End Date
January 10 2018
Last Update
February 5 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku, Japan
2
Chūbu, Japan
3
Kansai, Japan
4
Kanto, Japan